



PAUL R. LePAGE  
GOVERNOR

Maine Department of Health and Human Services  
MaineCare Services  
Pharmacy Unit  
11 State House Station  
Augusta, Maine 04333-0011

BETHANY L. HAMM  
ACTING COMMISSIONER

DUR COMMITTEE AGENDA

Date: Tuesday, December 11, 2018  
Time: 5:30PM to 8:30PM  
Location: Augusta Armory, 179 Western Avenue, Augusta, ME

- 1) Call to Order
- 2) MaineCare Updates
- 3) Public Comments
- 4) Old Business
  - Review of Minutes
  - Aimovig Criteria (1/1/2019)
  - Insulin Pumps (1/1/2019)
- 5) Closed Session
  - Drug Financial Information Review
- 6) New Business (open session)
  - Retro DUR
    - Data Presentation: Chronic Triptans Use
  - Retro DUR
    - Introduction: Vivitrol Adherence
  - New Drug Review

Ajoyy	Libtayo	Plixda
Altreno	Lokelma	Roxybond
Braftovi	Lumoxiti	Takhzyro
Delstrigo	Mektovi	Talzenna
Doptelet	Mulpeto	Tibsovo
Emgality	Nivestym	Vizimpro
Epidolex	Nocdurna	Xofluza
Firvanq	Orilissa	Ztlido
Ilumya	Perseris	
Jivi	Pifeltro	



PAUL R. LEPAGE  
GOVERNOR

Maine Department of Health and Human Services  
MaineCare Services  
Pharmacy Unit  
11 State House Station  
Augusta, Maine 04333-0011

BETHANY L. HAMM  
ACTING COMMISSIONER

A. FDA Safety Alerts

**FDA analysis finds no new or unexpected safety risks associated with Nuplazid (pimavanserin), a medication to treat the hallucinations and delusions of Parkinson's disease psychosis**  
[https://www.fda.gov/Drugs/DrugSafety/ucm621160.htm?utm\\_campaign=FDA%20analysis%20finds%20no%20new%20or%20unexpected%20safety%20risks%20associated%20with%20Nuplazid&utm\\_medium=email&utm\\_source=Eloqua](https://www.fda.gov/Drugs/DrugSafety/ucm621160.htm?utm_campaign=FDA%20analysis%20finds%20no%20new%20or%20unexpected%20safety%20risks%20associated%20with%20Nuplazid&utm_medium=email&utm_source=Eloqua)

B. Next Meeting (Tuesday, March 12, 2019 (from 5:30pm to 8:30pm)

C. Adjournment: 8:30PM